Loviride
Clinical data | |
---|---|
Other names | R089439; loveride[citation needed] |
ATC code |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Loviride is an experimental antiviral drug manufactured by
Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency.[1] It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR[2] and AVANTI[3]), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to the NNRTIs efavirenz and nevirapine
.
References
- ^ "Loviride". aidsmap.com. Archived from the original on 2007-09-27.
- S2CID 20008082.
- S2CID 22443598.